Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Bernstein Downgrades Lam Research to Market Perform

Bernstein analyst Stacy Rasgon downgrades Lam Research (NASDAQ:LRCX) from Outperform to Market Perform.
byBenzinga Newsdesk
March 13, 2023
1 minute read
Total
0
Shares
0
0
0
0
0
0

Bernstein analyst Stacy Rasgon downgrades Lam Research (NASDAQ:LRCX) from Outperform to Market Perform.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

Filed On May 19, DiaMedica Therapeutics A Complete Clinical Hold Response With FDA For Clinical Hold On A Phase 2/3 Clinical Trial Of DM199; Response With FDA Requesting Clinical Hold Imposed On Phase 2/3 Clinical Trial Of DM199 For AIS Be Lifted

By Benzinga Newsdesk
May 22, 5:17 PM
On May 22, 2023, DiaMedica Therapeutics Inc. (the "Company") announced that the Company filed on May 19, 2023 a complete clinical hold response with the U.S. Food and Drug Administration (the "FDA") requesting that the

DMAC